Trial Profile
A Clinical study to evaluate the safety and efficacy of Apatinib in EGFR-mutant TKI resistant patients with Non-small-cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology